FLT3
Hematologic System · Hematopoiesis, Erythropoiesis & Iron Homeostasis
Does FLT3 on a DNA report mean leukemia?
FLT3 makes a receptor that relays growth signals in certain cells, including blood-cell precursors. A tumor-associated FLT3 alteration requires a different interpretation from a variant found in consumer or inherited-DNA testing.
- Common Gene Name
- fms related receptor tyrosine kinase 3
- NCBI Gene ID
- 2322
- Chromosome
- 13
Clinical Evidence Status
Disease evidence limited or conflictingTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (7 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| leukemia, acute myeloid, susceptibility to | ClinGen gene-disease validity | Limited | Autosomal dominant | View source 2025-11-18 |
| Core binding factor acute myeloid leukemia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-12 | |
| Cytogenetically normal acute myeloid leukemia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-12 | |
| Gilteritinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Midostaurin (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Quizartinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Venetoclax (8) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Hematologic System